Drug Investigation

, Volume 8, Issue 6, pp 331–338 | Cite as

Prediction of Aminoglycoside Pharmacokinetic Parameters and Creatinine Clearance Using Bioelectrical Impedance

  • Carrie L. Coselman
  • Edward L. Peterson
  • Joseph S. BertinoJr
Original Research Article


Bioelectrical impedance is a noninvasive method used to determine body composition. Aminoglycosides are broad spectrum antibiotics that have a narrow therapeutic-to-toxic ratio. These agents have traditionally been administered using either population approaches (nomograms or Bayesian methods) or individualised pharmacokinetic monitoring, requiring blood sample analysis. Creatinine clearance is a useful measure of renal function that has been assessed using population approaches or by collecting a 12- to 24-hour urine specimen along with serum creatinine analysis. We investigated the use of bioelectrical impedance to determine predictor equations for the calculation of aminoglycoside pharmacokinetic parameters along with creatinine clearance in 20 noncritically ill patients receiving gentamicin or tobramycin. The bioelectrical impedance-derived model was able to explain >70% of the variance for half-life and total volume of distribution of aminoglycosides and >90% of the variance for creatinine clearance. Our model, when compared with a previously published model for gentamicin pharmacokinetic parameters, explained more of the variance for total volume of distribution and total body clearance. Bioelectrical impedance may be a useful tool for aminoglycoside dosing or for the determination of creatinine clearance in noncritically ill patients.


Adis International Limited Creatinine Clearance Aminoglycoside Tobramycin Drug Invest 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zarowitz BJ, Pilla AM. Bioelectrical impedance in clinical practice. DICP 1989; 23: 548–55PubMedGoogle Scholar
  2. 2.
    Brodie DA. Techniques of measurements of body composition Part I. Sports Med 1988; 5: 11–40PubMedCrossRefGoogle Scholar
  3. 3.
    Gentry CA, Rodvold KA, Bertino JS Jr. Methods of minimizing the cost of aminoglycoside therapy to hospitals. Phar-macoEconomics 1993; 3: 228–43Google Scholar
  4. 4.
    Zarowitz BJ, Pilla AM, Peterson EL. Bioelectrical impedance modelling of pharmacokinetic parameters. Br J Clin Pharmacol 1989; 28: 471–8PubMedCrossRefGoogle Scholar
  5. 5.
    Zarowitz BJ, Peterson E, Popovich Jr J. Relationship of bioelectrical impedance to pharmacokinetic parameters of theophyl-line in healthy males. Clin Pharmacokinet 1989; 17: 200–7PubMedCrossRefGoogle Scholar
  6. 6.
    Zarowitz BJ, Pila AM, Popovich Jr J. Expanded gentamicin volume of distribution in patients with indicators of malnutrition. Clin Pharmacol 1990; 9: 40–4Google Scholar
  7. 7.
    Zarowitz BJ, Robert S, Mlynarek M, et al. Determination of gentamicin pharmacokinetics by bioelectrical impedance in critically ill adults. J Clin Pharmacol 1993; 33: 562–7PubMedGoogle Scholar
  8. 8.
    Sawyer WT, Canaday BR, Poc TE, et al. Variables affecting creatinine clearance prediction. Am J Hosp Pharm 1983; 40: 2175–80PubMedGoogle Scholar
  9. 9.
    Smythe MA, Baumann TJ, Zarowitz BJ, et al. Relationship between values of bioelectrical impedance and creatinine clearance. Pharmacotherapy 1990; 10: 42–6PubMedGoogle Scholar
  10. 10.
    Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–5Google Scholar
  11. 11.
    Abbott Laboratories. TDX systems assay manual. Illinois: Abbott Laboratories, 1990Google Scholar
  12. 12.
    Kushner RF, Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr 1986; 44: 417–24PubMedGoogle Scholar
  13. 13.
    Gibaldi M, Perrier D. In: Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982Google Scholar
  14. 14.
    Bauer LA, Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci 1983; 72: 978–9PubMedCrossRefGoogle Scholar
  15. 15.
    SAS Institute Inc. SAS/STAT User’s Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc., 1989Google Scholar
  16. 16.
    Chatterjee S, Price B. In: Regression analysis by example. 2nd ed. New York: Wiley Publications, 1991: 234Google Scholar
  17. 17.
    Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983; 5: 161–8PubMedCrossRefGoogle Scholar
  18. 18.
    Hull JH, Sarubbi FA. Gentamicin serum concentrations: phar-macokinetic predictions. Ann Intern Med 1976; 85: 183–9PubMedGoogle Scholar
  19. 19.
    Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharma-cokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36: 679–81PubMedCrossRefGoogle Scholar
  20. 20.
    Levy J, Smith AL, Koup JR, et al. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984; 105: 117–24PubMedCrossRefGoogle Scholar
  21. 21.
    Zaske DE, Cippolle RJ, Strate RG, et al. Increased gentamicin dosage requirements: rapid elimination in 248 gynecology patients. Am J Obstet Gynecol 1981; 139: 896–900PubMedGoogle Scholar
  22. 22.
    Zaske DE, Sawchuck RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16: 824–38PubMedCrossRefGoogle Scholar
  23. 23.
    Lau A, Berk SI, Prosser T, et al. Estimation of creatinine clearance in malnourished patients. Clin Pharm 1988; 7: 62–5PubMedGoogle Scholar
  24. 24.
    O’Connell MB, Dwinell AM, Barnick-Mohrland DB. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992; 26: 627–35PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Carrie L. Coselman
    • 1
  • Edward L. Peterson
    • 2
  • Joseph S. BertinoJr
    • 1
    • 3
    • 4
  1. 1.Department of Pharmacy ServicesThe Mary Imogene Bassett HospitalCooperstownUSA
  2. 2.Henry Ford HospitalDetroitUSA
  3. 3.Department of MedicineThe Mary Imogene Bassett HospitalCooperstownUSA
  4. 4.Department of Pharmacy Services, Co-Director, Clinical Pharmacology Research CenterThe Mary Imogene Bassett HospitalCooperstownUSA

Personalised recommendations